	US 11,725,210 B2
	Immunomodulatory fusion proteins and uses thereof
Shannon K. Oda, Lake Forest Park, WA (US); Philip D. Greenberg, Mercer Island, WA (US); and Thomas M. Schmitt, Seattle, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Appl. No. 16/494,729
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US)
PCT Filed Mar. 16, 2018, PCT No. PCT/US2018/022998 § 371(c)(1), (2) Date Sep. 16, 2019, PCT Pub. No. WO2018/170475, PCT Pub. Date Sep. 20, 2018.
Claims priority of provisional application 62/629,663, filed on Feb. 12, 2018.
Claims priority of provisional application 62/473,282, filed on Mar. 17, 2017.
Prior Publication US 2020/0009190 A1, Jan. 9, 2020
Int. Cl. C07K 14/705 (2006.01); C12N 15/62 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01)

CPC C12N 15/62 (2013.01) [A61K 35/17 (2013.01); C07K 14/4705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

22 Claims

1. A fusion protein, comprising (a) an extracellular component comprising a binding domain that specifically binds a target, (b) an intracellular component comprising an intracellular signaling domain, and (c) a hydrophobic component connecting the extracellular and intracellular components,

wherein the extracellular component is or comprises (i) a CD95 (Fas) ectodomain that binds to CD95L (FasL) or (ii) a CD95L (FasL)-binding fragment of (i), and the intracellular component is or comprises a CD137 (4-1BB) intracellular signaling domain or a signal-producing portion thereof.